Personalis (NASDAQ:PSNL) Stock Price Down 8.1% - What's Next?

Key Points

• Personalis shares fell 8.1% intraday to $7.31 on Thursday, with only 302,397 shares traded—a 78% drop from the average session volume of about 1.35 million shares.
• Analysts are mixed but cautiously positive: six Buys, one Hold and one Sell give a consensus "Moderate Buy" rating and a $11 consensus price target, while BTIG and Guggenheim raised targets to $13 and Morgan Stanley cut its target to $10.
• The company beat quarterly estimates (EPS -$0.26 vs. -$0.31; revenue $17.35M vs. $17.12M) but remains unprofitable with a negative net margin of 116.69% and analysts projecting -1.4 EPS for the year.

Personalis, Inc. (NASDAQ:PSNL - Get Free Report) traded down 8.1% during mid-day trading on Thursday . The stock traded as low as $7.39 and last traded at $7.31. 302,397 shares traded hands during mid-day trading, a decline of 78% from the average session volume of 1,349,796 shares. The stock had previously closed at $7.95.

Analysts Set New Price Targets

PSNL has been the subject of several analyst reports. BTIG Research raised their price objective on shares of Personalis from $12.00 to $13.00 and gave the stock a "buy" rating in a report on Wednesday, February 11th. Morgan Stanley dropped their target price on Personalis from $11.00 to $10.00 and set an "equal weight" rating on the stock in a research report on Thursday, March 5th. Guggenheim raised their price target on Personalis from $12.00 to $13.00 and gave the stock a "buy" rating in a report on Monday, January 26th. Wall Street Zen upgraded Personalis from a "sell" rating to a "hold" rating in a research report on Sunday. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Personalis in a research note on Thursday, January 22nd. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Personalis currently has a consensus rating of "Moderate Buy" and a consensus price target of $11.00.

Personalis Price Performance

The firm's 50 day moving average is $8.86 and its 200 day moving average is $8.19. The company has a market cap of $709.71 million, a PE ratio of -7.46 and a beta of 2.02.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its earnings results on Thursday, February 26th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.05. The business had revenue of $17.35 million for the quarter, compared to analysts' expectations of $17.12 million. Personalis had a negative net margin of 116.69% and a negative return on equity of 39.13%. As a group, analysts anticipate that Personalis, Inc. will post -1.4 EPS for the current year.

Hedge Funds Weigh In On Personalis

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Royal Bank of Canada increased its stake in Personalis by 3.2% in the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company's stock worth $275,000 after acquiring an additional 2,395 shares during the last quarter. Dynamic Technology Lab Private Ltd boosted its position in shares of Personalis by 75.6% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 76,729 shares of the company's stock valued at $269,000 after acquiring an additional 33,044 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Personalis by 55.7% during the first quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company's stock worth $998,000 after purchasing an additional 101,706 shares in the last quarter. Focus Partners Wealth bought a new position in shares of Personalis in the first quarter worth approximately $47,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Personalis in the second quarter valued at approximately $451,000. 61.91% of the stock is currently owned by hedge funds and other institutional investors.

Personalis Company Profile

Personalis, Inc NASDAQ: PSNL is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company's core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.